Roche announced on Dec. 22, 2017 that it has agreed to fully acquire Ignyta, a San Diego, CA-based oncology company focused on precision medicine aiming to test, identify, and treat cancers with specific rare mutations, at a price of $27.00 per share in an all-cash transaction, or a total transaOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.